LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Dowlati, A., Harvey, R. D., Carvajal, R. D., Hamid, O., Klempner, S. J., Kauh, J. S. W., Peterson, D. A., Yu, D., Chapman, S. C., Szpurka, A. M., Carlsen, M., Quinlan, T., & Wesolowski, R. (2021). LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Investigational New Drugs, 39(4), 1057–1071. https://doi.org/10.1007/s10637-021-01084-8
Authors:
Afshin Dowlati
R. Donald Harvey
Richard D. Carvajal
Omid Hamid
Samuel J. Klempner
John Sae Wook Kauh
Daniel A. Peterson
Danni Yu
Sonya C. Chapman
Anna M. Szpurka
Michelle Carlsen
Tonya Quinlan
Robert Wesolowski
Affiliated Authors:
Richard D. Carvajal
Columbia Affiliation:
Author Keywords:
advanced solid tumor
csf-1
csf-1r inhibitor
il-34
immunotherapy
ly3022855
tumor -associated macrophages
elink
Publication Type:
Article
Unique ID:
10.1007/s10637-021-01084-8
PMID:
33624233
DOI:
10.1007/s10637-021-01084-8
Journal:
Investigational New Drugs
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: